An Observational Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Herceptin, Perjeta in Combination With Herceptin, or Kadcyla During Pregnancy or Within 7 Months Prior to Conception

Trial Profile

An Observational Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Herceptin, Perjeta in Combination With Herceptin, or Kadcyla During Pregnancy or Within 7 Months Prior to Conception

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 05 Jun 2017

At a glance

  • Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Trastuzumab emtansine (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions
  • Acronyms MotHER
  • Sponsors Genentech
  • Most Recent Events

    • 30 May 2017 Planned End Date changed from 1 Dec 2022 to 31 Jan 2025.
    • 30 May 2017 Planned primary completion date changed from 1 Dec 2022 to 31 Jan 2025.
    • 04 Dec 2012 Planned end date changed from 1 Dec 2019 to 1 Dec 2022 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top